ROTH Research

Yasmeen Rahimi, Ph.D., Director, Research Analyst

t: 646-616-2787, e: yrahimi@roth.com

Yasmeen Rahimi, Ph.D. is a Director, Research Analyst focused on biotechnology with particular interest in therapeutic areas encompassing nonalcoholic fatty liver disease (NASH), metabolic and rare diseases. Dr. Rahimi joined ROTH Capital directly from H.C. Wainwright & Co., where she worked as an equity research associate and before that, she was a research associate at Guggenheim Securities. Dr. Rahimi also worked as a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of clinical programs. Dr. Rahimi has extensive expertise in NASH and liver metabolism with 16 publications in highly prestigious journals. She trained at Yale University in the laboratory of Dr. Gerald Shulman, a world-renowned endocrinologist who pioneered the understanding of lipid-induced insulin resistance contributing to the pathogenesis of NASH. In addition, she completed her Ph.D. training in the laboratory of Dr. Robert A. Harris, a distinguished biochemist at Indiana University and a former trainee of Sir Hans Krebs, the “father of biochemistry”. Over the last several years, she utilized her understanding in NASH and metabolic diseases with bridging it to equity research through publications of in-depth industry notes, expert discussion series, and an investor conference. Dr. Rahimi earned her Ph.D. in Biochemistry with highest distinction from Indiana University School of Medicine. In addition, she has M.S. in Bioanalytical Chemistry from Purdue University, and a joint B.A. in German and Chemistry from Butler University.


Jotin Marango

Transactions // Privacy Policy // Conditions of Use // Initial Margin Disclosure Statement // Business Continuity Disclosure // Best Execution Reports // Contact ROTH // Locations
Annual Notice of Important Policies and Disclosures
Copyright ©2017 ROTH Capital Partners, LLC // Member FINRA/SIPC